U.S. markets closed
  • S&P Futures

    4,395.25
    +0.75 (+0.02%)
     
  • Dow Futures

    34,939.00
    -14.00 (-0.04%)
     
  • Nasdaq Futures

    14,940.75
    -7.00 (-0.05%)
     
  • Russell 2000 Futures

    2,194.10
    +7.40 (+0.34%)
     
  • Crude Oil

    72.14
    +0.49 (+0.68%)
     
  • Gold

    1,802.50
    +2.70 (+0.15%)
     
  • Silver

    24.78
    +0.13 (+0.53%)
     
  • EUR/USD

    1.1825
    -0.0001 (-0.01%)
     
  • 10-Yr Bond

    1.2340
    -0.0420 (-3.29%)
     
  • Vix

    19.36
    +1.78 (+10.13%)
     
  • GBP/USD

    1.3879
    +0.0000 (+0.00%)
     
  • USD/JPY

    109.7970
    +0.0300 (+0.03%)
     
  • BTC-USD

    39,726.74
    +2,785.48 (+7.54%)
     
  • CMC Crypto 200

    932.07
    +55.84 (+6.37%)
     
  • FTSE 100

    6,996.08
    -29.35 (-0.42%)
     
  • Nikkei 225

    27,703.38
    -266.84 (-0.95%)
     

GlaxoSmithKline, Vir Biotechnology Seek Emergency FDA Authorization For COVID-19 Drug

·2 min read

GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc. (NASDAQ: VIR) have submitted an application to the Food and Drug Administration requesting emergency use authorization for VIR-7831, an investigational dual-action SARS-CoV-2 monoclonal antibody for the treatment of adults and adolescents with mild-to-moderate COVID-19 who are at risk for a severe worsening of their condition.

What Happened: The VIR-7831 project began in April 2020 when the companies began a partnership to develop solutions to combat coronaviruses.

The preclinical data suggests VIR-7831 could potentially block viral entry into healthy cells while also clearing infected cells, the companies said, noting that “the antibody binds to an epitope on SARS-CoV-2 that is shared with SARS-CoV-1 (the virus that causes SARS), indicating that the epitope is highly conserved, which may make it more difficult for resistance to develop.”

Earlier this month, a Phase 3 trial evaluating VIR-7831 as a monotherapy for the early treatment of COVID-19 showed an 85% reduction in hospitalization or death from those receiving VIR-7831 versus those receiving a placebo.

As a result, the Independent Data Monitoring Committee coordinating the trial recommended a halt in patient enrollment based on the efficacy level.

Related Link: GSK Out-Licenses Two Drug Candidates To Boston Pharmaceuticals

What Happens Next: GlaxoSmithKline and Vir Biotechnology are also in discussions with the European Medicines Agency and other global regulators for similar emergency authorizations in order to make VIR-7831 widely and quickly available.

Separate from this endeavor, GlaxoSmithKline is collaborating with other companies, including Sanofi (NASDAQ: SNY), CureVac (NASDAQ: CVAC) and Medicago Inc. on the development of COVID-19 vaccines.

Related Link: 3 Biotech Stocks That Could Double In 12 Months

Photo by Daniel Roberts / Pixabay.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.